Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,641 Million (Small Cap)
19.00
NA
1.28%
-0.50
6.97%
1.36
Revenue and Profits:
Net Sales:
329 Million
(Quarterly Results - Jun 2025)
Net Profit:
43 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.55%
0%
-7.55%
6 Months
32.9%
0%
32.9%
1 Year
37.49%
0%
37.49%
2 Years
15.67%
0%
15.67%
3 Years
11.45%
0%
11.45%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Bide Pharmatech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.95%
EBIT Growth (5y)
-5.85%
EBIT to Interest (avg)
67.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.17
Sales to Capital Employed (avg)
0.51
Tax Ratio
23.78%
Dividend Payout Ratio
68.18%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.29%
ROE (avg)
5.99%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
1.36
EV to EBIT
11.19
EV to EBITDA
8.74
EV to Capital Employed
1.71
EV to Sales
1.40
PEG Ratio
0.26
Dividend Yield
1.28%
ROCE (Latest)
15.28%
ROE (Latest)
6.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
329.00
268.10
22.72%
Operating Profit (PBDIT) excl Other Income
58.10
37.50
54.93%
Interest
1.30
2.50
-48.00%
Exceptional Items
-1.00
0.90
-211.11%
Consolidate Net Profit
42.70
25.80
65.50%
Operating Profit Margin (Excl OI)
146.40%
98.90%
4.75%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 22.72% vs -0.11% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 65.50% vs -44.75% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,095.30
1,086.70
0.79%
Operating Profit (PBDIT) excl Other Income
154.20
139.70
10.38%
Interest
5.30
4.40
20.45%
Exceptional Items
3.50
-13.00
126.92%
Consolidate Net Profit
117.40
108.40
8.30%
Operating Profit Margin (Excl OI)
100.90%
90.70%
1.02%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.79% vs 30.94% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 8.30% vs -25.75% in Dec 2023
About Bide Pharmatech Co., Ltd. 
Bide Pharmatech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






